Ono Pharmaceutical
As of the edition of 20 October 2026, Ono Pharmaceutical runs 54 drugs, 20 of them marketed; it is on route A at 7 targets and on route B at 17 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 20 |
| Active | 15 |
| Went quiet | 9 |
| Stopped | 9 |
| Status not established | 1 |
| Total | 54 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Nivolumab | Ends 2031 (orphan exclusivity) | 2 |
| Sitagliptin | Ends 2026 (patent) | 1 |
| Carfilzomib | Ends 2028 (exclusivity) | 2 |
| Remimazolam | none listed | 0 |
| Aprepitant | none listed | 2 |
| Binimetinib | Ends 2033 (patent) | 6 |
| Encorafenib | Ends 2030 (exclusivity) | 3 |
| Rivastigmine | none listed | 4 |
| Ivabradine | Ends 2026 (patent) | 3 |
| Opicapone | Ends 2032 (patent) | 2 |
| Fosaprepitant | none listed | 3 |
| Etelcalcetide | Ends 2031 (patent) | 1 |
| Landiolol | Ends 2029 (exclusivity) | 1 |
| Tirabrutinib | none listed | 0 |
| Anamorelin | none listed | 0 |
| Imidafenacin | none listed | 2 |
| Minodronic acid | none listed | 2 |
| Sepetaprost | none listed | 0 |
| Pranlukast | none listed | 1 |
| Metyrosine | none listed | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 7 targets, route B at 17 targets.
All 24 rows on route A or B
In the product24 company-target rows on route A or B; 21 are not shown here, and no score is.
See all 24 targets where Ono Pharmaceutical needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 21 trials led
- Nervous system: 17 trials led
- Digestive system: 13 trials led